14th Biennial Meeting

Tudor ArmsApril 2nd – 5th, 2014
Tudor Arms Doubletree Hotel
Cleveland, OH | USA

Overview of the Meeting

The 14th Biennial Meeting of the International Society for Applied Cardiovascular Biology (ISACB) will convene in Cleveland, OH, USA, April 2-5, 2014 at the Tudor Arms Doubletree Hotel located midway between the campuses of the Cleveland Clinic and Case Western University/University Hospitals and is organized by the International Society for Applied Cardiovascular Biology (ISACB), a professional society founded in 1987. The goal of the conference is to establish a research agenda going forward that will address and resolve barriers to the understanding and translation of discoveries in cardiovascular medicine into therapeutic modalities that improve public health. This conference will provide a forum for cardiovascular researchers working in research laboratories in academia, in industry and in the clinics to convene to disseminate new information in their fields, build relationships with one-another and hopefully renew and establish new collaborations and strategies for translating advancements derived from the understanding of the biology of cardiovascular disease to the care and management of patients. The focus of the conference will be upon translation of basic research relevant to regenerative therapies including stem cells, tissue interactions and cardiovascular biomaterials and novel cardiovascular diagnostics, imaging and therapeutics. A dedicated plenary session will focus upon issues related to regulatory science and commercialization.

The 14th Biennial Meeting of ISACB celebrates 25 years of focus of this group in translation of cardiovascular science which allows for reflections from the past in the field and informs the agenda of research in the field going forward. Members of the Local Organizing Committee are from Summa Health System in Akron, the Cleveland Clinic and Case Western Reserve University.

Objectives and Format

The following specific objectives of the conference have been established:

(1) to address the critical issues in the clinical implementation of cell-based therapies for cardiovascular disease including the potential clinical relevance of stem cell therapies and their translation into the clinic
(2) to communicate new research findings in cardiovascular mechano-biology and pathobiology and to understand their implications in clinical care
(3) to better understand the interactions of biomaterials with tissues and their implications in improving cardiovascular device design and utilization
(4) to discuss novel cardiovascular diagnostics, imaging and therapeutics and their relevance to clinical care and
(5) to identify barriers and solutions to issues of translation, regulatory science and commercialization.

These meeting objectives will be addressed by a roster of nationally and internationally respected investigators whose research work is relevant to translational cardiovascular biology that have been invited to present their latest research results. In addition, the plenary sessions will include brief, oral presentations of selected, peer-reviewed proffered abstracts relevant to each session theme and the programmatic objectives. Ample time will be built into the program for structured discussion of issues focused upon how to apply the presented concepts to clinical cardiovascular therapies and/or how clinical observations can be addressed by basic research methodologies. Ample time will also be built into the program for non-structured opportunities for collegial conversation and information exchange and collaboration building. Researchers presenting posters relevant to the topics will be encouraged to hang their posters on the first day of the conference and maintain that posting for the duration of the conference. At mid-conference, a specific block of time will be dedicated to an interactive poster session so that attendees can meet and converse with poster authors regarding data interpretation and relevance of the presented work to translational cardiovascular therapeutic strategies.

A “satellite program” preceding the conference will be held at the Lerner Research Institute on the campus of the Cleveland Clinic organized by ISACB and Marc Penn, M.D., Ph.D., entitled “Stem Cells for Disease Modeling and Regenerative Therapeutics.”

Allan D. Callow, M.D., Ph.D. Young Investigator Awards

ISACB has historically been very successful in encouraging participation in its Biennial Meetings by researchers in training programs. It is again an objective for the 2014 meeting to encourage submission of abstracts and participation by young scientists from the United States and throughout the world who are considering a career relevant to applied or translational cardiovascular research. Five Allan D. Callow, M.D., Ph.D. Young Investigator Awards will be presented to authors of these outstanding research submissions. To qualify for the Young Investigator Award, the presenting author must be responsible for the scientific content of the abstract and be in a “training” program (postdoctoral fellow, resident, graduate student or medical student). The abstracts of all Young Investigator Award applicants will be blindly reviewed and ranked by a subcommittee of the conference Program Committee. The authors of the top 5 ranked abstracts will receive the awards. The funding from this R13 Conference Award would support attendance by trainees at the conference.

Organizing Committees

The main organizing committee for the 14th Biennial Meeting has consisted of the following ISACB executive committee leaders:

  • David Vorp, PhD – University of Pittsburgh – Current ISACB President
  • Frederick J. Schoen, MD, PhD – Brigham & Women’s Hospital – ISACB Past President
  • Howard Greisler, MD – Loyola School of Medicine – ISACB Past President
  • Elena Aikawa, MD, PhD – Brigham & Women’s Hospital – ISACB Officer
  • Steven Schmidt – Summa Health System – ISACB Executive Committee Member

Collectively, the main Organizing Committee recruited research leaders from the Cleveland/Akron area who have been involved in ISACB activities in the past to serve on a Local Organizing Committee. These leaders include:

  • Marc S. Penn, MD, PhD – Cardiovascular Institute, Summa Health System
  • Paul DiCorleto, PhD – Lerner Research Institute, Cleveland Clinic
  • Linda Graham. MD – Vascular Surgery, Cleveland Clinic
  • Paul Fox, PhD – Lerner Research Institute, Cleveland Clinic
  • James Anderson, MD, PhD – Department of Pathology, Case Western Reserve University
  • Nicholas Ziats, PhD – Department of Bioengineering, Case Western Reserve University

Together the main and local organizing committees have programmatic and logistic responsibility for the configuration and successful execution of the program. The design of the program and its objectives, recruitment of speakers, review of abstracts and advocacy for the meeting are collective responsibilities of these committees.

Scientific Program

As of the date of this posting, all plenary sessions have been identified and session co-chairs have been recruited. The chairs are currently extending invitations to potential invited speakers for inclusion in their sessions. A preliminary draft agenda of the Scientific Program including names and affiliations of confirmed co-session chairs is included below.

Satellite Meeting

Wednesday, April 2, 2014: 2-5 pm
Lerner Research Center (on the campus of the Cleveland Clinic) Room NE1-205
Requires separate registration

Program Title: “Stem Cells for Disease Modeling and Regenerative Therapeutics

Program Organizer: Marc S. Penn, MD, PhD  Summa Health System & Northeast Ohio Medical University

Invited Speakers:

  • Keith March, MD, PhD – Indiana University School of Medicine
  • Stan Gerson, MD – Case Western Reserve University
  • Robert Deans, PhD – Exec VP Regenerative Medicine, Athersys, Inc. – Therapeutic response pathways and development of adult stem cells for CNS injury and disease
  • Feng Dong, MD, PhD Northeast Ohio Medical University - Stem cell strategies for post-AMI cardiac repair in diabetes
  • Dan Simionescu, PhD Clemson University - Bioengineering challenges in heart valve tissue regeneration
  • Marc. S. Penn, MD, PhD Summa Cardiovascular Institute, Summa Health System and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University – Stem cell homing for tissue repair

ISACB Meeting Keynote Speaker  

Friday, April 4, 2014

Speaker: Alexander W. Clowes, MD – V. Paul Gavora and Helen S. and John A. Shilling Endowed Chair of Vascular Surgery, Department of Surgery, University of Washington

Topic: Vein Graft Stenosis – Does it Have a Genetic Origin?

Plenary Sessions

Thursday, April 3, 2014 (8am) thru Saturday, April 5, 2014 (1pm)

Session I: Cardiovascular Mechanobiology
                   Co-sponsored by the Biomedical Engineering Society (BMES)

Session Co-chairs:

  • David Vorp, PhD – University of Pittsburgh
  • Elena Aikawa, MD, PhD – Brigham and Women’s Hospital; Harvard Medical School

Session Invited Speakers and Topics:

  • David Merryman, PhD – Vanderbilt University – Mechanobiological mechanisms in calcific aortic valve disease
  • Tina Rinker, PhD – University of Calgary – Nanoparticle interactions with the endothelium
  • Steven A. Fisher, MD – University of Maryland Baltimore  – Smooth muscle cell biology and mechanobiology
  • Elena Aikawa, MD, PhD – Brigham and Women’s Hospital  – Matrix vessels in cardiovascular calcification

Session Proffered Abstract Presentations:

  • Joseph Chen – Vanderbilt University – The role of Notch1 mechanobiology in calcific aortic valve disease
  • Samantha Ratley – University of Notre Dame – The role of bicuspid aortic valve hemodynamics in acute aortic dilation
  • Meghan A. Bowler – Vanderbilt University – Dimethyl Celecoxib blocks cadherin-11 mechanotransduction and calcification of valvular fibroblasts
  • Jason R. Cook – Icahn School of Medicine at Mount Sinai New York – Characterization of dilated cardiomyopathy in mice with Marfan Syndrome
  • Frederick W. Damen – Purdue University – 4-dimensional ultrasound imaging of left-ventricular dynamics
Session II: Cardiovascular Biomaterials, Tissue Interactions and Pathobiology
                     Co-sponsored by the Society for Biomaterials (SFB)

Session Co-chairs:

  • Howard Greisler, MD – Loyola University Stritch School of Medicine 
  • Nicholas P. Ziats, PhD – Case Western Reserve University

The session is designed to address the dichotomies of the effects of materials on biology and the effects of biology upon materials in the development of the next generation of more clinically efficacious cardiovascular biomaterials.

Session Invited Speakers and Topics:

  • Paul DiCorleto, PhD – Cleveland Clinic – Role of inflammatory mechanisms in vascular biology and physiology
  • Daniel I. Simon, MD – University Hospitals Case Medical Center – S100A9 in vascular inflammation and thrombosis
  • Toshiharu Shinoka, MD, PhD – Nationwide Children’s Hospital – Current status of tissue engineered vascular grafts in pediatric cardiac surgery
  • Mukesh Jain, MD – Case Cardiovascular Research Institute – Circadian Control of Vascular Disease

Session Proffered Abstract Presentations:

  • Jun-ichiro Koga – Harvard Med School and Brigham and Women's Hospital – Macrophage notch signaling accelerates vein graft disease in Ldlr-/- mice
  • Hiroshi Iwata – Brigham and Women's Hospital  – Global proteomic analysis reveals Parp14 as a novel regulator of macrophage activation
  • Julie A. Phillippi – University of Pittsburgh – Bicuspid aortic valve patients exhibit superoxide accumulation in the ascending aorta
  • Dmitry O. Traktuev – Indiana University  – Activin A is a key modulator of endothelial and adipose stromal cell interactions
  • Dena C. Wiltz – Rice University – Presence of Ryanodine receptor isoforms 2 and 3 and the mineralization action of Lysophosphatidylcholine through the Ryanodine receptor in valvular interstitial cells
Session III: Novel Cardiovascular Diagnostics, Imaging and Therapeutics
                      Co-sponsored by the Society for Cardiovascular Pathology (SCVP)

Session Co-Chairs:

  • Paul DiCorleto, PhD – Cleveland Clinic
  • Daniel I. Simon, MD – University Hospitals Case Medical Center

Session Invited Speakers:

  • Marc S. Penn, MD, PhD Summa Cardiovascular Institute, Summa Health System and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University – Multi-marker approach for cardiovascular risk assessment 
  • Saptarsi Haldar, MD Case Cardiovascular Research Institute  Bromodomain inhibition in heart failure – placing BETS on Chromatin
  • Farouc Jaffer, MD, PhD – Massachusetts General Hospital  Intravascular molecular imaging of inflammation and proteolyic activity in atherosclerosis
  • Eric Brey, MD – Illinois Institute of Technology – Imaging Challenges in biomaterials and tissue engineering

Session Proffered Abstract Presentations:

  • Sandeep Kumar – Emory University  – Inhibition of mechanosensitive microrna-712 decreases endothelial inflammation and atherosclerosis
  • Nicole F. Steinmetz – Case Western Reserve University – Bio-inspired nanoparticle-based reperfusion therapy
  • Noah Johnson – University of Pittsburgh – Controlled delivery of sonic hedgehog morphogen for cardiac repair
  • Jeffrey T. Krawiec – University of Pittsburgh – Defective smooth muscle cell recruitment by adipose-derived mesenchymal stem cells from elderly patients:  A cautionary tale for autologous vascular tissue engineering
Session IV: Tissue Remodeling, Cell-based Therapies and Tissue Engineering for
                      Cardiovascular Disease
                      Co-sponsored by the North American Vascular Biology Organization (NAVBO)

Session Co-Chairs:

  • Frederick Schoen, MD, PhD  –  Brigham and Women’s Hospital and Harvard University
  • Keith March, MD, PhD – Indiana Center for Vascular Biology and Medicine, Indiana University School of Medicine

Session Invited Speakers:

  • Keith March, MD, PhD – Indiana University School of Medicine – Adipose stem cells in angiogenesis, vasculogenesis and tissue repair
  • Anand Ramamurthi, PhD – Cleveland Clinic – Stem cell therapy for abdominal aortic aneurysm
  • Amit Patel, MD  – University of Utah – Optimizing biological therapies for cardiac disease

Session Proffered Abstract Presentations:

  • Benjamin R. Green  – University of Pittsburgh  – Phenotypic diversity of perivascular progenitor cells from human aorta
  • Olga Stenina-Adognravi  – Cleveland Clinic  – Tissue-specific regulation of hyperglycemia-induced angiogenesis
  • Stuart K. Williams  – Cardiovascular Innovation Institute – 3d bioprinting of cardiovascular tissues
  • Deirdre E. J. Anderson – Oregon Health & Science University – In vitro markers of endothelial hemostatic function predict ex vivo and in vivo performance of flow-conditioned endothelialized ePTFE grafts
  • Robert A. Allen  – University of Pittsburgh  – Nerve and elastin regeneration on elastic and fast-resorbing vascular grafts
Session V:    Translation, Regulatory Science and Commercialization
                       Co-sponsored by the Global Cardiovascular Innovation Center (GCIC)

Session Co-Chairs:

  • Simon Hoerstrup, MD, PhD – University Hospital Zurich
  • Ivan Vesely, PhD – ValveXchange, Inc.

Session Invited Speakers:

  • Simon Hoerstrup, MD, PhD – University Hospital Zurich – Clinical translation of tissue engineered substitutes for pediatric patients (on both sides of the Atlantic) – US/EU FIM trials
  • Ivan Vesely, PhD – ValveXchange, Inc. – Strategies in selecting a clinical trial site in different parts of the world
  • Art Coury, PhD – Coury Consulting Services – Commercialization of regenerative products: The academic/industry partnership
  • Avi Fischer, MD, FACC, FHRS – St. Jude Medical - Medical device innovation from concept to commercialization:  Challenges and opportunities in the new healthcare environment
  • Mark Low, Managing Director – Global Cardiovascular Innovation Center (GCIC) – New resources for translation of early stage biomedical innovations from the research laboratory to commercial development


Thursday Post-luncheon speaker: 
Roland Fasol, MD, PhD, Head of Cardiac Surgery, The Jilin Heart Hospital, Changchun, China – Challenges to start a modern heart hospital in rural China

Panel Discussion25 Years of Applied Cardiovascular Biology: Where have we been? Where are we going? What are our greatest opportunities?
Panel Moderator:  Frederick Schoen, MD, PhD – Brigham and Women’s Hospital

         Invited Panelists:

  • Linda Graham, MD – Cleveland Clinic
  • James Anderson, MD, PhD – Case Western Reserve University
  • Alexander Clowes, MD – University of Washington
  • Howard Greisler, MD – Loyola University
  • Michael Wolf – Medtronic, Inc.
  • D.Geoffrey Vince, PhD – Cleveland Clinic

Interactive Poster Session

All posters accepted for presentations will be posted throughout the meeting. However, it is the tradition of ISACB to host an interactive poster sessions at which poster authors stand with their poster and interact with meeting attendees providing the opportunity for engagement and discussion. The interactive poster session will be held at the midpoint of the meeting.

Late-Breaking Abstract Podium Presentations

Session Co-Chairs:

  • Alexander Clowes, MD – University of Washington
  • Gary Bowlin, PhD University of Memphis 

The following late-breaking abstracts will be presented:

  • M.K. Sewell-Loftin – Vanderbilt University, Nashville, TN – Myocardial contractile forces regulate epithelial to mesencymal transformation in endocardial cells
  • Joshua D. Hutcheson – Brigham and Women’s Hospital and Harvard Medical School, Boston, MA – Plaque-destabilizing microcalcifications: Novel insights into atherosclerotic plaque vulnerability
  • Juan Melero-Martin – Boston Children’s Hospital, Boston, MA – Endothelial paracrine regulation of human mesenchymal stem cell engraftment
  • Mohammed S. El-Kurdi – Neograft Technologies, Inc. – Effecting in-situ remodeling of saphenous vein bypass grafts using a conformal electrospun external support
  • Keith Gooch – Ohio State University, Columbus, OH – Arterial levels of oxygen stimulate intimal hyperplasia in human saphenous veins via a ROS-dependent mechanism

Corporate Sponsors

Gold Level Sponsorship


Silver Level Sponsorship



Supporter Level Sponsorship


Satellite Meeting Corporate Sponsor






Session Co-Sponsors

Session I:  Cardiovascular Mechanobiology
Co-sponsored by Biomedical Engineering Society (BMES)


Session II:  Cardiovascular Biomaterials, Tissue Interactions and Devices
Co-sponsored by


Session III:  Novel Cardiovascular Diagnostics, Imaging and Therapeutics
Co-sponsored by Society for Cardiovascular Pathology (SCVP)

Session IV:  Tissue Remodeling, Cell-based Therapies and Tissue Engineering for Cardiovascular Disease
Co-sponsored by


Session V:  Translation, Regulatory Science and Commercialization
Co-sponsored by




Connect with ISACB Instagram Twitter LinkeIn

© 1987 - 2023 The International Society for Applied Cardiovascular Biology